BackgroundDrug-induced gingival overgrowth (DIGO) as an interdisciplinary clinical challenge, faces dual therapeutic barriers due to its unclear pathogenesis and high recurrence rate, forcing clinicia
Data relating to the study reported in the paper "Quality, scope and reporting standards of randomised controlled trials in Irish Health Research: an observational study".
